EP1054004A1 — Novel pyrimidine-5-carboxamide derivatives
Assigned to Astellas Pharma Inc · Expires 2000-11-22 · 25y expired
What this patent protects
Pyrimidine-5-carboxamide derivatives represented by a general formula (I) or salts thereof [wherein each symbol has the following meaning; X: O, S, NR 1 , CO, NR 1 CO, CONR 1 , C=N-OR 1 or a bond, Y: a lower alkylene group which may be substituted by OR 1 or -NHR 1 , or …
USPTO Abstract
Pyrimidine-5-carboxamide derivatives represented by a general formula (I) or salts thereof [wherein each symbol has the following meaning; X: O, S, NR 1 , CO, NR 1 CO, CONR 1 , C=N-OR 1 or a bond, Y: a lower alkylene group which may be substituted by OR 1 or -NHR 1 , or a bond, Z: O, NR 2 or a bond, A: H, or a lower alkyl which may have a substituent, a -CO-lower alkyl which may have a substituent, an aryl which may have a substituent, a heteroaryl which may have a substituent, a cycloalkyl which may have a substituent or a nitrogen-containing saturated heterocyclic group which may have a substituent, B: an aryl which may have a substituent or a heteroaryl group which may have a substituent, R 1 , R 2 : H, a lower alkyl or a -CO-lower alkyl group].
Drugs covered by this patent
- Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.